9102 related articles for article (PubMed ID: 17668534)
1. Cytokine therapy in advanced melanoma.
Kalaaji AN
J Drugs Dermatol; 2007 Apr; 6(4):374-8. PubMed ID: 17668534
[TBL] [Abstract][Full Text] [Related]
2. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
Kirkwood JM; Moschos S; Wang W
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2331s-2336s. PubMed ID: 16609054
[TBL] [Abstract][Full Text] [Related]
3. Interferon, interleukin-2, and other cytokines.
Buchbinder EI; McDermott DF
Hematol Oncol Clin North Am; 2014 Jun; 28(3):571-83. PubMed ID: 24880948
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy for malignant melanoma.
Stoutenburg JP; Schrope B; Kaufman HL
Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
Kirkwood JM; Tarhini AA
Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
[TBL] [Abstract][Full Text] [Related]
7. [Interferon: therapy in patients with cutaneous malignant melanoma in adjuvant setting].
Wcisło G; Szczylik C
Pol Merkur Lekarski; 2003 Jul; 15(85):5-8. PubMed ID: 14593950
[TBL] [Abstract][Full Text] [Related]
8. Biochemotherapy of melanoma.
Keilholz U
Forum (Genova); 2003; 13(2):158-65; quiz 189. PubMed ID: 14732882
[TBL] [Abstract][Full Text] [Related]
9. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
Melanoma Res; 2008 Apr; 18(2):152-60. PubMed ID: 18337653
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.
Daud AI; Mirza N; Lenox B; Andrews S; Urbas P; Gao GX; Lee JH; Sondak VK; Riker AI; Deconti RC; Gabrilovich D
J Clin Oncol; 2008 Jul; 26(19):3235-41. PubMed ID: 18591558
[TBL] [Abstract][Full Text] [Related]
11. Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence.
Hemrajani RH; Kim KB; Amos WR; Mann DE
Melanoma Res; 2007 Aug; 17(4):257-9. PubMed ID: 17625458
[No Abstract] [Full Text] [Related]
12. Correspondence re: G. C. de Gast et al., Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000.
Meyers FJ; O' Donnell RT
Clin Cancer Res; 2000 Oct; 6(10):4167. PubMed ID: 11051273
[No Abstract] [Full Text] [Related]
13. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.
Bins A; Mallo H; Sein J; van den Bogaard C; Nooijen W; Vyth-Dreese F; Nuijen B; de Gast GC; Haanen JB
J Immunother; 2007; 30(2):234-9. PubMed ID: 17471170
[TBL] [Abstract][Full Text] [Related]
14. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous melanoma: available therapy for metastatic disease.
Tarhini AA; Agarwala SS
Dermatol Ther; 2006; 19(1):19-25. PubMed ID: 16405566
[TBL] [Abstract][Full Text] [Related]
16. Treatment approaches for advanced cutaneous melanoma.
Stein JA; Brownell I
J Drugs Dermatol; 2008 Feb; 7(2):175-9. PubMed ID: 18335655
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
Lutzky J; Weber R; Nunez Y; Gillett M; Spitler L
J Immunother; 2009 Jan; 32(1):79-85. PubMed ID: 19307996
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
Schuchter LM
J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
[No Abstract] [Full Text] [Related]
19. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
Bartell HL; Bedikian AY; Papadopoulos NE; Dett TK; Ballo MT; Myers JN; Hwu P; Kim KB
Head Neck; 2008 Dec; 30(12):1592-8. PubMed ID: 18798304
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy, cytokines, and biochemotherapy for melanoma.
Eton O
Cancer Chemother Biol Response Modif; 2005; 22():739-48. PubMed ID: 16110637
[No Abstract] [Full Text] [Related]
[Next] [New Search]